Glutathione vs Glutamine: How They Differ

The short answer: two different molecules

Glutamine is a single amino acid. Glutathione is a tripeptide, meaning three amino acids joined by peptide bonds: glutamate, cysteine and glycine. They are not interchangeable names for the same substance, and they are not isomers or salts of each other. The confusion is understandable, because both names begin with the same root and because glutamine, glutamate and glutathione sit close together in the same area of nitrogen and redox metabolism.

For general background on what glutathione is and what the literature covers, see the glutathione glossary entry and the overview guide what is glutathione used for. For the broader distinction between single amino acids, peptides and proteins, see amino acids vs peptides. This page focuses only on the comparison.

Head-to-head trials: what exists

No head-to-head human trial randomising participants to glutathione versus glutamine, with a shared primary endpoint, was identified in the published literature reviewed for this page. Because of that, the two cannot be placed on a single ranked scale from the trial record, and no comparative claim of superiority is available to report. What follows instead is a side-by-side description of two separate evidence bases, which differ in population, setting and study design, and which therefore do not answer the same question.

Composition and structure

The gamma-glutamyl linkage is what makes glutathione unusual among small peptides, since it joins the side chain carboxyl of glutamate rather than the alpha carboxyl. Related gamma-glutamyl compounds have been described separately in the chemistry literature; a 2005 paper reviewed gamma-L-glutamyltaurine, a naturally occurring gamma-glutamyl amino acid derivative, and discussed its chemistry and biological characterisation (PMID 15838590). That family of molecules illustrates why glutathione is classified as a peptide while glutamine is classified as an amino acid.

How glutamine and glutathione are connected in metabolism

The two molecules are linked, but indirectly. Glutamine can be converted to glutamate, and glutamate is one of the three residues in glutathione. Glutamate is also traded across the cell membrane for cystine, the oxidised dimer of cysteine, which supplies the second glutathione residue. Two reviews of the cystine/glutamate antiporter system described SLC7A11 (xCT) as importing cystine in exchange for exporting glutamate, and connected that exchange to intracellular glutathione levels and to protection of cancer cells from ferroptosis (PMID 33000412; PMID 29764521).

Several laboratory studies examined the glutamine side of that relationship. A 2015 report in Molecular Cell found that glutaminolysis, together with transferrin-mediated iron handling, regulated ferroptosis in the cell and tissue models studied (PMID 26166707). A 2019 study examined the role of mitochondria in ferroptosis triggered by cysteine deprivation and described mitochondrial metabolism as a participant rather than a bystander in that form of cell death (PMID 30581146). A 2020 study identified a variant of the SLC1A5 transporter that delivered glutamine into mitochondria and supported metabolic reprogramming in cancer cells (PMID 31866442).

Taken together, these reports describe a supply chain rather than an equivalence: glutamine can contribute carbon and nitrogen upstream, and glutathione is one of several downstream products that depend on that supply (PMID 26166707; PMID 33000412). None of that preclinical work established that giving one molecule to a person raises or substitutes for the other.

Why so much of the mechanistic literature is oncology

Much of the detailed mapping of glutamine handling comes from cancer biology, where tumour cells often show heavy glutamine use. A 2013 study in Nature reported that pancreatic cancer cells used a KRAS-regulated glutamine metabolic pathway to maintain redox balance and support growth (PMID 23535601). A 2022 study found that silencing GOT2 reprogrammed glutamine metabolism and sensitised hepatocellular carcinoma models to glutaminase inhibitors (PMID 35895805). A 2025 report described targeting glutamine dependency in pancreatic cancer models and found that this conferred vulnerability to GPX4-dependent ferroptosis (PMID 39879992).

Related work extended the theme to drug resistance and to immune cells. Researchers reported in 2023 that SLC38A5 modulated ferroptosis in pancreatic cancer models and was involved in gemcitabine resistance (PMID 37887353), and a 2025 study in Cell Metabolism described HEBP2-governed competition for glutamine between tumour cells and macrophages as a determinant of immunotherapy efficacy in triple-negative breast cancer models (PMID 40992373). These are mechanistic cancer studies in cells and animal models. They do not describe supplementation in healthy people, and they should not be read as such.

Human evidence base for glutamine

The clinical literature on glutamine is largest in supportive care during cancer treatment. A 2020 review in Nutrients examined glutamine for amelioration of radiation and chemotherapy associated mucositis during cancer therapy, summarising the rationale for supplementation in that setting and the clinical studies conducted in it (PMID 32512833). That review also situated glutamine as a conditionally essential amino acid whose demand may rise during illness and treatment (PMID 32512833). The review format means it pooled and interpreted published trials rather than generating new randomised data.

An important caution runs through the mechanistic literature above: because tumour models frequently depend on glutamine (PMID 23535601; PMID 40992373), the question of supplementation in oncology populations is one that the published supportive-care literature has had to address directly rather than assume (PMID 32512833).

Human evidence base for glutathione

The glutathione human literature is a separate body of work from the papers cited on this page, and the verified citation set used here does not include glutathione supplementation trials. For that reason, no specific glutathione trial result, endpoint or effect size is asserted on this page. The overview pages linked above cover what has been published on oral glutathione in human volunteers. What can be stated here without a trial citation is structural and regulatory: glutathione is a tripeptide (PMID 33000412), and its intracellular level in model systems has been tied to cystine availability through the SLC7A11 exchanger (PMID 29764521).

Regulatory status in the United States

In the United States, oral glutathione is sold as a dietary supplement. The FDA does not approve dietary supplements for efficacy before they are sold; manufacturers are responsible for safety and labelling, and premarket approval of effectiveness is not part of that pathway. That status is distinct from prescription medicines and from intravenous administration, which appear in the literature only as study design elements or as the subject of regulatory warnings. No glutathione product has FDA approval for skin lightening.

Glutamine has a split status. It is widely sold as a dietary supplement, under the same framework in which the FDA does not approve efficacy before sale. Separately, an oral prescription L-glutamine powder has FDA approval for a specific haematologic indication, which places that particular product in the drug pathway rather than the supplement pathway. Regulatory approval attaches to a specific product and a specific indication, not to a molecule in general, so supplement-grade glutamine does not inherit the approved drug's status.

Adverse Events: What Studies Report

The verified papers cited on this page are predominantly mechanistic cancer biology and do not function as safety datasets for supplementation in healthy adults. The 2020 Nutrients review of glutamine in radiation and chemotherapy associated mucositis is the one clinically oriented source cited here, and it discussed glutamine supplementation in that oncology setting alongside the questions that setting raises (PMID 32512833). Readers looking for tolerability data should consult primary trial reports for the specific product and population of interest, since safety findings are specific to route, formulation and population.

On the mechanistic side, researchers reported that glutamine metabolism supported tumour growth in pancreatic cancer models (PMID 23535601) and that competition for glutamine between tumour cells and macrophages influenced immunotherapy response in breast cancer models (PMID 40992373). Those are model-system observations about tumour biology, not reported adverse events in human volunteers, and the distinction matters when interpreting headlines about either molecule.

Summary of the differences

• Structure: glutathione is a three-residue peptide; glutamine is one amino acid.
• Relationship: glutamine can feed the glutamate pool upstream of glutathione synthesis, and glutamate exchange for cystine has been tied to glutathione levels in model systems (PMID 33000412).
• Comparative trials: none identified that tested both against a shared endpoint, so no comparative ranking can be drawn.
• Evidence shape: the glutamine literature cited here spans clinical supportive care (PMID 32512833) and extensive cancer metabolism work (PMID 35895805), while the glutathione material cited here is mechanistic and redox focused (PMID 30581146).
• Regulation: both are sold as supplements in the US without premarket efficacy approval; approval status differs at the level of specific drug products, not molecules.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decisions about supplements, medicines or medical care.

References

• Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy (Protein & Cell, 2021)
• Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer (Cancer Communications, 2018)
• Glutaminolysis and Transferrin Regulate Ferroptosis (Molecular Cell, 2015)
• Role of Mitochondria in Ferroptosis (Molecular Cell, 2019)
• A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells (Cell Metabolism, 2020)
• Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway (Nature, 2013)
• GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors (Cancer Research, 2022)
• Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis (Cell Reports Medicine, 2025)
• SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer (Cells, 2023)
• HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer (Cell Metabolism, 2025)
• Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy (Nutrients, 2020)
• gamma-L-glutamyltaurine (Amino Acids, 2005)